JCR 2026 Released: What the New Impact Factor Numbers Actually Show Medical Authors

The 2026 Journal Citation Reports landed on June 17, right on Clarivate's usual mid-June schedule, and the numbers are now available to anyone with a Web of Science subscription. The headline figure is large: 22,643 journals across 254 subject categories now carry a Journal Impact Factor. But for medical authors who need to make submission decisions in the weeks ahead, the headline figure is the least interesting part of this release. What matters more is where the new journals came from, how continuing policy changes have altered some familiar impact factors, and what the growing open access footprint in the JCR means for choosing where to publish.

This post is about the actual results, not the anticipated ones. The goal is to help you read the numbers correctly so you are not drawing the wrong conclusions from comparisons that do not account for the methodological changes baked into this edition.

What Two Policy Changes Did to the Numbers

Before getting to the broader trends, it is worth addressing the methodological changes directly, because they affect how any individual impact factor should be read in 2026.

The first change is the exclusion of citations to and from retracted articles from the Journal Impact Factor numerator. Clarivate implemented this in JCR 2025 as an integrity measure, and it continues in 2026. For journals in fields with elevated retraction activity, the effect can be noticeable: a journal whose IF was partly built on citations to papers that were subsequently retracted will show a lower 2026 figure, even if every new paper it published was sound. Clinical nutrition, cardiology, and oncology have all seen elevated retraction rates in recent years, and journals in those fields are among those where this policy has measurable downstream effects.

The second change concerns Early Access content. Articles that appear online before being formally assigned to a journal issue are now included in the denominator of the impact factor calculation. This means journals that routinely publish large volumes of Early Access material can see their IF diluted, because the denominator grows faster than citations to those early articles accumulate. High-volume publishers and journals with aggressive online-first pipelines are disproportionately affected.

The practical implication is that a year-over-year impact factor comparison requires context. A journal with a lower 2026 IF than 2025 may have changed nothing about its editorial standards, peer review depth, or the quality of papers it attracts. It may simply have published more Early Access content, or lost a portion of its citation numerator to retraction exclusions. Before concluding that a journal has declined in your field, check its JCI (discussed below) and look at whether any of these structural factors apply to its publishing model.

521 New Journals and the Geographic Shift They Represent

The most striking finding in the 2026 release is not the aggregate journal count but the composition of the 521 journals that received a Journal Impact Factor for the first time. These journals come from 47 countries and regions, and 58% of them are based outside the United States and Western Europe. This is a deliberate expansion of the index, and it signals a shift in what Clarivate is treating as globally significant scholarship.

For medical authors, the location of these new journals matters for a few reasons. Researchers working on topics with strong research communities in Asia, South Asia, Latin America, or Africa may now find that journals closer to those communities have received a JIF for the first time, giving them a metric-backed option that did not previously exist. A clinician researcher in Southeast Asia studying infectious disease, or a physician scientist in sub-Saharan Africa investigating HIV outcomes, has more credentialed regional options in 2026 than in 2024.

For researchers at institutions where promotion panels still weigh impact factors heavily, the question of whether a newly indexed journal will be recognized is real. The answer in most contexts is: it depends on how quickly the institution updates its journal evaluation frameworks. A JIF, however new, is a JIF in the JCR. Whether a hiring or promotion committee at a North American medical school treats it the same as an established journal with a longer track record is a softer institutional question, not a metric one.

If you are considering an early submission to one of the 521 newly indexed journals, evaluate the editorial board carefully. A journal that earned its first JIF in 2026 through credible peer review and a legitimate citation history is a different proposition from a journal that achieved indexing through volume and speed. The JIF alone does not distinguish between them at this stage.

Where Research Output Is Growing: China, India, and What That Means

The author affiliation data that underlies the JCR is illuminating this year. Mainland China and the United States together account for 48% of author affiliations in the Web of Science data covering the 2023 to 2025 period. Over that same window, the regions with the largest increases in author representation are Mainland China (up 23%) and India (up 12%).

These figures reflect a structural change in global research output, not a temporary spike. China's investment in biomedical research infrastructure has been sustained for over a decade. India's research output has grown more recently but is accelerating across clinical medicine, epidemiology, and basic science. The practical consequence for impact factor calculations is that citation patterns in many clinical fields are now influenced by the reading and citing behaviors of large research communities in these countries. Journals that are widely read and trusted in Chinese and Indian academic medicine are accumulating citations from those communities, and their IFs are moving accordingly.

For a cardiologist in the United States deciding between submitting to a journal with an IF of 7 and one with an IF of 5, the question of which journal is more read by the field now partly depends on which research communities have been driving citations in that specialty. That is not a reason to chase IF indiscriminately, but it is a reason to look at who is actually citing papers in your subspecialty rather than assuming the IF hierarchy in your field has remained constant.

Open Access Growth: 6% More Gold OA Journals

The 2026 JCR shows a 6% increase in the number of Gold open access journals in the database, rising from 6,320 to 6,703. This continues a multi-year trend that is being driven by a combination of factors: funder mandates, institutional open access agreements, and the growing credibility of fully OA journals across most medical specialties.

The composition of this growth matters. Many of the newly Gold OA journals that entered the JCR recently are not startups. They are journals that converted from subscription or hybrid models under pressure from funders such as HHMI, the Gates Foundation, and Wellcome, all of which have placed significant restrictions on hybrid publishing in recent years. When a journal that already had a strong citation record and a well-regarded editorial board converts to Gold OA, its impact factor tends to remain stable or rise, because the citation base was already there.

For authors, this means the idea that choosing open access means accepting a lower-prestige venue is becoming harder to sustain in most medical disciplines. It was already difficult in fields like medicine, where PLOS Medicine, BMJ Open, and several nature portfolio journals have carried strong IFs while operating as fully OA for years. It is becoming harder across a wider range of specialties as more converted journals establish their 2026 impact factors.

The caveat remains the article processing charge. Gold OA in the JCR is not synonymous with affordable OA. APCs across the database range from zero (for diamond OA journals supported by institutions or societies) to over $11,000 for some journals in the Nature and Cell Press families. Knowing that a Gold OA journal carries a JIF tells you nothing about the fee. That information requires a separate check against the journal's APC schedule and your funder's coverage policies.

Suppression: What It Means That Some Journals Lose Their IF

Every year, Clarivate temporarily suppresses a subset of journals from the JCR because their impact factor figures appear distorted. The distortions Clarivate looks for are specific: unusually high rates of self-citation, citation stacking arrangements where two or more journals cite each other at anomalously high rates, or other patterns that suggest the impact factor has been artificially inflated rather than earned through genuine field influence.

Suppressed journals remain indexed in the Web of Science. They continue to be searchable, their papers remain citable, and their ISSN numbers remain valid. What they lose is the JIF number for that year. In JCR 2025, 20 journals lost their impact factors through this mechanism. The 2026 suppression figures will become clear as researchers access the release, but the policy applies with the same criteria.

For medical authors, the relevance of suppression is subtle but real. A journal can appear credible, indexed, and active while being under a JIF suppression for citation anomalies. If you are evaluating a journal that has an unusually high impact factor relative to what you would expect for its tier, checking its self-citation rate in the JCR profile is worth doing. Clarivate displays this figure publicly in the journal detail view. A self-citation rate above 30 to 40 percent in a journal that is not a highly specialized technical outlet is a signal worth investigating before you commit a significant manuscript.

The Journal Citation Indicator: The Number Worth Using More

Alongside the Journal Impact Factor, the 2026 JCR continues to surface the Journal Citation Indicator (JCI) as a complementary field-normalized metric. The JCI adjusts for citation patterns within a specific field and document type, which addresses the most persistent problem with the standard JIF: it is not comparable across disciplines. A Journal Impact Factor of 8 means something quite different in gastroenterology than it does in immunology or surgery.

The JCI expresses performance relative to the expected citation rate for that journal's category. A JCI of 1.0 means the journal performs at the field average. A JCI above 1.0 means it performs better than average for its category. This makes cross-specialty comparisons more honest and makes it easier to assess whether a journal with a modest absolute JIF is actually a strong performer in its field.

For medical authors comparing journals across subspecialties, the JCI is the better starting point. If you are deciding between submitting a diabetes management paper to a general medicine journal with an IF of 14 and a specialist endocrinology journal with an IF of 6, looking at the JCI of both against their respective categories tells you more about relative standing than the raw numbers. The specialist journal with a JCI of 1.8 in its category is likely more influential for readers who matter for a clinical endocrinology paper than the general journal with a JCI of 0.9.

The JCI is also more stable under the policy changes affecting the JIF this year. Because it normalizes by field, the effects of retraction exclusions in high-retraction fields are partially accounted for in the field baseline, rather than falling entirely on the affected journal's relative standing.

Quartile Updates: What Changed and What Did Not

The JCR quartile ranking (Q1 through Q4) is recalculated fresh with each annual release, which means that some journals shift quartiles from one year to the next even when their absolute impact factor has not changed dramatically. Quartile position depends on where a journal falls relative to all other journals in its category. If the category distribution shifted because of the policy changes described earlier, journals that stayed stable in absolute terms may have moved up or down in quartile relative to peers that shifted.

Medical authors who track quartile standing for promotion, tenure, or grant applications should pull a current snapshot from the JCR interface now that the 2026 release is live, rather than relying on what appeared on a journal's website in May. The quartile listed on many journal websites as of late May or early June reflects JCR 2025 data. The 2026 data is live as of June 17, and any quartile claims made on journal websites should be treated as provisional until verified against the current release.

This is a more frequent source of error than most authors realize. A journal that was Q1 as of May 2026 on its own website may be Q2 in JCR 2026 if enough journals in its category moved upward due to citation growth. The opposite is also possible: a journal that looked like Q2 in 2025 data may have entered Q1 in 2026 because adjacent journals declined. Do not assume last year's quartile applies to the manuscript you are submitting this month.

What the JIF Still Does Not Tell You

The JCR 2026 is a more transparent and methodologically careful release than prior editions, but the core limitation of the JIF is unaltered. The impact factor is a journal-level metric calculated on a distribution with a long right tail. A handful of highly cited papers carry the aggregate figure upward for any given journal, while the majority of papers published in that same journal receive far more modest citation counts. The figure of 78.5 for the New England Journal of Medicine, or 88.5 for the Lancet, does not mean that the average paper in those journals receives 78 or 88 citations. It means that some papers pulled the average to that level.

For the working researcher deciding where to submit a solid but not landmark clinical study, the practical import is that a high-IF journal is not necessarily a high-citation journal for papers of a certain type. A well-targeted submission to a specialist journal with a JIF of 5 that is read every week by the 2,000 clinicians who make decisions in your subspecialty may generate more actual clinical influence than a submission to a generalist journal with a JIF of 30 where your paper competes for attention with major cardiovascular trials and pandemic-related research.

The metrics that track downstream impact, things like citation in clinical guidelines, policy documents, or systematic reviews, are not captured in the JCR. Altmetric scores, download counts, and uptake in clinical practice registries give different signals. For authors whose research has direct clinical policy relevance, checking these alongside the JIF is genuinely informative in a way the JIF alone is not.

A Practical Checklist for Using JCR 2026 Data Right Now

The JCR 2026 release is not a reason to reconsider your entire submission strategy. It is a reason to do a targeted verification for the journals you are actively considering. A few specific checks are worth making now that the data is live.

First, if you have been tracking a target journal based on its 2025 JIF, pull its 2026 number and look at whether it changed. If it dropped, consider whether the Early Access or retraction-exclusion effects might explain it before concluding the journal has lost standing in the field. If it rose, check the self-citation rate to confirm the improvement reflects genuine citation growth rather than a methodological artifact.

Second, confirm the journal's current quartile in its primary category. Do not trust what appears on the journal's own website until you verify it against the JCR 2026 interface directly. Journal websites update their quartile badges at different speeds, and some will still display 2025 figures for weeks or months after the new release.

Third, if you are comparing journals across different medical specialties, use the JCI rather than the JIF as your primary comparison. A specialist endocrinology journal and a general internal medicine journal are not fairly compared by raw JIF. The JCI puts both on the same normalized scale within their respective categories.

The release of the JCR is a moment to update your mental model of where the journals in your field stand relative to each other. It is not the moment to abandon the submission target you have been preparing for. If the journal you have been aiming at looks largely unchanged, or changed in ways that do not affect your calculation, there is no reason to redirect. The metrics are a supporting input, not the primary reason to choose a venue.

What to Watch in the Months Ahead

The 2026 release is one data point in a continuing story. Several things are worth tracking over the rest of the year.

The suppression list for 2026 will become clearer as more researchers examine the database. When journals are suppressed, they typically do not announce it prominently. Authors discover it when they look up a familiar journal and find no JIF listed. If a journal you have published in previously or are planning to submit to does not appear to have a 2026 impact factor in the JCR interface, it may be suppressed rather than deindexed. The distinction matters because suppression is a one-year event that the journal can recover from, while deindexing has longer consequences.

The growth trajectory of Chinese and Indian research output is not going to reverse. Over the next two to three JCR cycles, the journals that attract sustained citation from those communities will accumulate stronger impact factors in a measurable way. Researchers in fields with dense output from those regions should track this trend actively, because their submission strategies may benefit from aligning with journals that are genuinely influencing clinical practice in the world's largest research communities rather than aiming for journals optimized for a North Atlantic readership that is now a minority of global output.

Finally, the continued growth in Gold OA journals within the JCR is likely to accelerate under the HHMI and Gates mandates that are now fully in force. Authors at institutions with broad open access agreements covering major publishers can increasingly choose OA routes without personal APC cost, which changes the economics of the submission decision. Watch for further transformative agreement announcements from major research institutions and consortia in the second half of 2026, as these agreements reshape which journals are cost-free to OA authors and therefore which journals attract their submissions.

Further Reading